ArticleNature2022
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 779 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
779citing papers in PubMed, 1 pooled it
72.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
779 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,192 citations in OpenAlex.
- Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2.Nature communications · 2024Trial
- Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.Emerging microbes & infections · 2026Article
- Infection of urban rodents by SARS-CoV-2 in COVID-19 healthcare facilities in Brazzaville, Republic of the Congo.One health outlook · 2026Article
- Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study.Signal transduction and targeted therapy · 2026Article
- Article
- Article
- Dose-dependent effects of recombinant spike protein-based vaccination on SARS-CoV-2 evolutionary dynamics and the emergence of variants in hamster models.The Journal of general virology · 2026Article
- Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants.Research square · 2026Article
- Dissecting serum polyclonal antibody escape to SARS-CoV-2 variants by deep mutational learning.Cell reports methods · 2026Article
- The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives.Antibodies (Basel, Switzerland) · 2026Review
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- COVID-19 morbidity and mortality in young people in selected countries of the Americas.International journal for equity in health · 2026Review
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- Article
- Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.Nature microbiology · 2026Article
- A Cross-Sectional Study Shows Emergence of the Delta, 19B, 20A, 20B, 19A, and Omicron Variants of SARS-CoV-2 in Burkina Faso: A Conundrum Within a Conundrum.Health science reports · 2026Article
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
719 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
56 authors at 16 institutions in 7 countries.
Elisabetta Cameroni *Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
John E Bowen *Department of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3590-9727
Laura E Rosen *Vir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8030-0219
Christian Saliba *Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Samantha K ZepedaDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0005-9793
Katja CulapHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-0956-0018
Dora PintoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Laura A VanBlarganDepartment of Medicine, Washington University of School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8922-8946
Anna De MarcoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Julia di IulioVir Biotechnology, San Francisco, CA, USA.
Fabrizia ZattaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Hannah KaiserVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3991-7401
Julia NoackVir Biotechnology, San Francisco, CA, USA.
Nisar FarhatVir Biotechnology, San Francisco, CA, USA.
Nadine CzudnochowskiVir Biotechnology, San Francisco, CA, USA.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2880-3927
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0007-2226
Josh R DillenVir Biotechnology, San Francisco, CA, USA.
Abigail E PowellVir Biotechnology, San Francisco, CA, USA.
Alex ChenVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2620-5066
Cyrus MaherVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6666-3574
Li YinVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2634-9158
David SunVir Biotechnology, San Francisco, CA, USA.
Leah SoriagaVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5852-741X
Jessica BassiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chiara Silacci-FregniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Claes GustafssonATUM, Newark, CA, USA.
Nicholas M FrankoDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8165-6332
Jenni LogueDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7889-8960
Najeeha Talat IqbalDepartment of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
Ignacio MazzitelliInstituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Jorge GeffnerInstituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Renata GrifantiniNational Institute of Molecular Genetics, Milan, Italy.
Helen ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Andrea GoriInfectious Disease Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Agostino RivaDepartment of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC), Università di Milano, Milan, Italy.ORCID http://orcid.org/0000-0003-3171-3049
Olivier GianniniFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Alessandro CeschiFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.ORCID http://orcid.org/0000-0002-4308-0405
Paolo FerrariFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.ORCID http://orcid.org/0000-0002-9619-3104
Pietro E CippàDepartment of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Christian GarzoniClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0002-1648-1625
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0001-5061-8296
Christy HebnerVir Biotechnology, San Francisco, CA, USA.
Lisa A PurcellVir Biotechnology, San Francisco, CA, USA.
Luca PiccoliHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-1085-6502
Matteo Samuele PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0001-5776-654X
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9636-8330
Michael S DiamondDepartment of Medicine, Washington University of School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8791-3165
Amalio TelentiVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6290-7677
Herbert W VirginVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8580-7628
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA. gsnell@vir.bio.ORCID http://orcid.org/0000-0003-1475-659X
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.ORCID http://orcid.org/0000-0002-6019-8675
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.ORCID http://orcid.org/0000-0002-5797-1364
VIR Biotechnology (United States) · USVir Biotechnology (Switzerland) · CHUniversity of Washington · USWashington University in St. Louis · USClinica Luganese Moncucco · CHEnte Ospedaliero Cantonale · CHHoward Hughes Medical Institute · USUniversidad de Buenos Aires · ARUniversity of Wisconsin–Madison · USAga Khan University · PKATUM (United States) · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto Nazionale Genetica Molecolare · ITUniversity of Milan · ITUniversity of Zurich · CHUNSW Sydney · AU
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MUniversity of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MTRAINING IN MOLECULAR BIOPHYSICST32GM008268 · NIGMS · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M, ZHENG, NING · 1988 to 2023
$8.6MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MStructural Studies of Coronavirus Fusion ProteinsR01GM120553 · NIGMS · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2016 to 2020
$1.7MHoward Hughes Medical InstituteNIAID NIH HHS 75N93021C00014NIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201400008CNIAID NIH HHS HHSN272201700059CNIAID NIH HHS U01 AI151698NIGMS NIH HHS R01 GM120553NIGMS NIH HHS T32 GM008268
Abstract
The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising concerns about the effectiveness of available vaccines and antibody-based therapeutics. Here we show that the Omicron RBD binds to human ACE2 with enhanced affinity, relative to the Wuhan-Hu-1 RBD, and binds to mouse ACE2. Marked reductions in neutralizing activity were observed against Omicron compared to the ancestral pseudovirus in plasma from convalescent individuals and from individuals who had been vaccinated against SARS-CoV-2, but this loss was less pronounced after a third dose of vaccine. Most monoclonal antibodies that are directed against the receptor-binding motif lost in vitro neutralizing activity against Omicron, with only 3 out of 29 monoclonal antibodies retaining unaltered potency, including the ACE2-mimicking S2K146 antibody
Indexed as
Neutralization TestsAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralAntigenic Drift and ShiftBroadly Neutralizing AntibodiesCell LineConvalescenceCOVID-19 VaccinesEpitopes, B-LymphocyteHumansImmune EvasionMiceACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 VaccinesEpitopes, B-LymphocyteS2H97 antibodyS2X259sotrovimabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.